期刊
JOURNAL OF NEPHROLOGY
卷 36, 期 3, 页码 659-661出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s40620-022-01504-9
关键词
-
A male patient with multiple sclerosis (MS) developed kidney disease and proteinuria during therapy with Ocrelizumab. Kidney biopsy revealed focal segmental glomerulosclerosis (FSGS). This case suggests a potential association between Ocrelizumab therapy and the development of FSGS.
We describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria. Kidney biopsy showed focal segmental glomerulosclerosis (FSGS) and Ocrelizumab treatment was stopped. Teriflunomide is less likely to have caused FSGS due to a three week wash-out period and a timespan of 15 months between the last Teriflunomide dose and development of albuminuria. Treatment with Ocrelizumab has been associated with organ-specific inflammation in MS-patients, thus an association between the development of FSGS and Ocrelizumab therapy is possible, and this case suggests considering this potential association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据